Small Study Offers Hope For PARP/PD-L1 Combos In Prostate Cancer
Executive Summary
National Cancer Institute's Phase II combo data for AstraZeneca's PARP inhibitor Lynparza and PD-L1 inhibitor Imfinzi are encouraging, but more research is needed to show a role for immunotherapy combinations in advanced prostate cancer.
You may also be interested in...
How The Prostate Cancer Market Will Look Over Next Decade
As generic competition to J&J's Zytiga starts to line up ahead of possible launches in October, Datamonitor Healthcare has been weighing up the prostate cancer therapy space and seeing where the future competition will come from for Pfizer and Astellas' market leader Xtandi.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.